SUPPORT
Cancer
CANCER
FOxTROT was funded by Cancer Research UK (grant reference: C551/A8283; recipient: D.M.). Additional support was provided by the Birmingham and Leeds ECMC network, the RCS Eng and Rosetrees Trust, and the Swedish Cancer Society. Panitumumab was provided free of charge by Amgen, who also supported 